Zynerba Pharmaceuticals is a pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS) and 22q11.2 deletion syndrome.

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

COM:ZYNERBA

Zynerba Pharmaceuticals, Inc.

Last Close

1.27

10/10 20:00

Market Cap

70.12M

Beta: -

Volume Today

861.74K

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics